



December 18, 2012

For Immediate Release

**UMN Pharma Announces Collaboration with ILDONG Pharmaceutical  
for Recombinant Influenza HA Vaccines in South Korea**

**Akita, Japan, December 18, 2012** UMN Pharma Inc. (“UMN Pharma”; headquarters: Akita, President & CEO: Tatsuyoshi Hirano) announced today that its board resolved to enter into an agreement with ILDONG Pharmaceutical Co., Ltd. (“ILDONG”; headquarters: Seoul, Chairman & CEO: Jung-chi Lee), on December 28, 2012, for co-development and exclusive commercialization of recombinant influenza HA vaccines, UMN-0502, UMN-0501 and UMN-0901 (the “Products”) in the Republic of Korea (the “Territory”).

The Products are cell culture based influenza HA vaccines manufactured using a Baculovirus Expression Vector System (“BEVS”) developed by Protein Sciences Corporation in the United States (“PSC”). UMN-0502 is a seasonal influenza HA vaccine, and UMN-0501 and UMN-0901 are HA vaccines for H5N1 and H9N2 influenza viruses, respectively. UMN Pharma has exclusive rights to the Products for development and commercialization in Japan, Republic of China, Republic of Korea, Taiwan, Hong Kong and Singapore. In Japan, UMN Pharma is co-developing UMN-0502 (under Phase III clinical trials) and UMN-0501 (under Phase II clinical trials) with Astellas Pharma Inc. PSC has finalized Phase III clinical trials for UMN-0502 in the United States and has filed a Biologics License Application with the U.S. Food and Drug Administration.

Under this agreement, ILDONG obtains co-development and exclusive commercialization rights for the Products in the Territory, and UMN Pharma receives an upfront payment upon execution of the agreement and milestone payments when certain development stages are achieved. Also, UMN Pharma agreed to manufacture and supply bulk vaccines for the final commercial products at set price to be determined separately.

UMN Pharma has taken its first step toward East Asia through this agreement. UMN Pharma expects that the value of these recombinant influenza HA vaccines will be maximized by cooperating with ILDONG, a leading pharmaceutical company in the Republic of Korea.

For more information, contact:  
Business Development Division  
Tel: +81-45-624-8341  
e-mail: [press@umnpharma.com](mailto:press@umnpharma.com)